Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATNM 
Actinium Pharmaceuticals Inc (ATNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ATNM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5
1 Year Target Price $5
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.26% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.54M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 5 | Beta -0.3 | 52 Weeks Range 1.03 - 2.41 | Updated Date 09/15/2025 |
52 Weeks Range 1.03 - 2.41 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.18% | Return on Equity (TTM) -130.59% |
Valuation
Trailing PE - | Forward PE 6.84 | Enterprise Value -7788698 | Price to Sales(TTM) 652.71 |
Enterprise Value -7788698 | Price to Sales(TTM) 652.71 | ||
Enterprise Value to Revenue 1726.07 | Enterprise Value to EBITDA -3.62 | Shares Outstanding 31195900 | Shares Floating 30858663 |
Shares Outstanding 31195900 | Shares Floating 30858663 | ||
Percent Insiders 1.79 | Percent Institutions 20.88 |
Upturn AI SWOT
Actinium Pharmaceuticals Inc
Company Overview
History and Background
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company, founded in 2006, focused on the development of innovative targeted radiotherapies for patients with hematologic malignancies. The company is advancing a pipeline of Actinium-225 based therapies.
Core Business Areas
- Therapeutics Development: Focused on developing targeted radiotherapies for hematologic malignancies, utilizing Actinium-225.
Leadership and Structure
Sandesh Seth, Chairman and CEO. The company has a standard board of directors and executive management structure.
Top Products and Market Share
Key Offerings
- Iomab-B: Iomab-B (Bexarotene iodine I 131 tositumomab) is in development for targeted conditioning before bone marrow transplant in relapsed or refractory Acute Myeloid Leukemia (AML). Market share data is not readily available due to its development stage. Competitors in AML treatment include companies developing chemotherapies, targeted therapies, and immunotherapies, such as Pfizer (PFE), Novartis (NVS), and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The radiopharmaceutical market is growing due to advancements in targeted therapies and increasing prevalence of cancer. The industry is competitive with many companies developing various therapies.
Positioning
Actinium is positioned as a specialized biopharmaceutical company focused on Actinium-225 based targeted radiotherapies for hematologic malignancies. Their competitive advantage lies in their targeted radiotherapy approach.
Total Addressable Market (TAM)
The radiopharmaceutical market is estimated to be in the billions of dollars, and growing. Actinium is positioned to capture a portion of this market through its targeted therapies, contingent on regulatory approvals and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary Actinium-225 platform
- Targeted radiotherapy expertise
- Potential for breakthrough therapies in hematologic malignancies
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other cancer types
- Positive clinical trial results leading to regulatory approval
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established cancer therapies
- Manufacturing complexities of radiopharmaceuticals
Competitors and Market Share
Key Competitors
- PFE
- NVS
- BMY
Competitive Landscape
Actinium faces strong competition from established pharmaceutical companies with broader product portfolios. Its success hinges on demonstrating superior efficacy and safety in targeted indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its pipeline and securing partnerships.
Future Projections: Future growth is dependent on the success of Iomab-B clinical trials and potential FDA approval. Analyst estimates vary widely.
Recent Initiatives: Advancing Iomab-B in Phase 3 clinical trials, exploring new Actinium-225 based therapies.
Summary
Actinium Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on targeted radiotherapies. Its strengths lie in its proprietary platform and expertise in Actinium-225, but it faces challenges related to funding, clinical trial success, and competition. The company's future depends heavily on the successful development and commercialization of Iomab-B and other pipeline candidates. They need to look out for the larger companies PFE, NVS and BMY
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Actinium Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters New York, NY, United States | ||
IPO Launch date 2012-12-27 | Chairman & CEO Mr. Sandesh C. Seth M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.actiniumpharma.com |
Full time employees 27 | Website https://www.actiniumpharma.com | ||
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.